Evidence map›Paper›PMID 41513540›Full record

ArticleEBioMedicine2026

Cross-binding antibodies capable of neutralising diverse hantaviruses are produced in response to Puumala virus infection.

Jordan J Clark, Stefan Hatzl, Kirill Vasilev, Robert Andreata-Santos, Jeremy S Yong, Eva Mittler, Ezgi Kasikci, Kartik Chandran, Viviana Simon, Robert Krause and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Generation and Characterization of the Human Anti-HTNV Antibody KJJ4.International journal of molecular sciences · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jordan J ClarkDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Stefan HatzlIntensive Care Unit, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Kirill VasilevDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Robert Andreata-SantosDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA; Retrovirology Laboratory, Department of Microbiology, Immunology and Parasitology, Paulista School of Medicine, Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil.
Jeremy S YongDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Eva MittlerDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA.
Ezgi KasikciDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA.
Kartik ChandranDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA.
Viviana SimonDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; The Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Robert KrauseDivision of Infectious Disease, Department of Internal Medicine, Medical University of Graz, Graz, Austria. Electronic address: robert.krause@medunigraz.at.
Florian KrammerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Ignaz Semmelweis Institute, Interuniversity Institute for Infection Research, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness at the Medical University of Vienna, Vienna, Austria. Electronic address: florian.krammer@meduniwien.ac.at.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOrthohantaviruses (hantaviruses) are emerging rodent-borne pathogens that can cause severe human disease. They are present on multiple continents and are responsible for thousands of human cases per year. Despite this, no licenced therapeutics are available, vaccines for most strains are lacking, and the immunological response to infection is poorly characterised. This study aimed to analyse the humoral immune response to Puumala virus (PUUV) infection to inform future studies focussing on the production of therapeutic monoclonal antibodies and vaccination strategies.

methodsSerum was obtained from a cohort of 24 patients hospitalised with PUUV infection at four time points, covering the early acute, late acute, early convalescent, and late convalescent stages of the disease. The humoral immune responses at each time point were quantified, and cross-binding, cross-neutralising antibody responses were investigated. Serum cytokine levels were also interrogated, and expression was correlated with humoral outputs.

findingsPUUV infection elicited a robust anti-PUUV neutralising antibody response. However, cross-reactive antibodies that were capable of binding diverse hantaviruses were also induced in late convalescence. Modulations in the abundance of IgG subclasses were evident following infection, with significant differences present months after infection.

interpretationThis study demonstrates that broadly reactive anti-hantavirus antibodies are produced in response to Old-World hantavirus infection, but predominantly months after recovery. As this is concomitant with changes in IgG subtypes, our results suggest that PUUV infection promotes prolonged class-switching and somatic hypermutation, favouring conserved epitopes long after exposure.

fundingWork at Mount Sinai was supported by Institutional Funds, work at the Medical University of Vienna was supported by Institutional Funds. The study was supported in part by the Styrian government, Austria (project no. ABT12-106729/2022-13) and the Austrian Science Fund (FWF) (number J 4737-B).

Indexed as

Antibodies, NeutralizingAntibodies, ViralHemorrhagic Fever with Renal SyndromeOrthohantavirusPuumala virusAdultCross ReactionsCytokinesFemaleHumansImmunity, HumoralImmunoglobulin GMaleMiddle AgedAntibodies, NeutralizingAntibodies, ViralCytokinesImmunoglobulin GAntibodiesCytokinesOrthohantavirusPuumalaSerology

Identifiers

PMID41513540
PMCPMC12905621

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.